Emilio Pando, MD
Internal Medicine · Miramar, FLNPI 1710920400
Payments from drug & device makers
What this record shows
This record is dominated by education: $15 of the $15 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Boehringer Ingelheim. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 1 payment — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$15
Across 33 payments — averaging $10,263 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Currax Pharmaceuticals LLC$250K
- Sanofi US Services Inc.$89K
What the payments were for
- Education$15100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $15 |
How this compares
$15 in reported general payments places this provider in the 10th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $34,820 |
| JanuviaSitagliptin Phosphate | 24 | $27,806 |
| XareltoRivaroxaban | 12 | $18,989 |
| FarxigaDapagliflozin Propanediol | 16 | $15,847 |
| EntrestoSacubitril/Valsartan | 13 | $9,457 |
| MyrbetriqMirabegron | 15 | $9,285 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,590 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $6,506 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $6,039 |
| Atorvastatin Calcium | 255 | $4,189 |
| Celecoxib | 52 | $3,753 |
| Levothyroxine Sodium | 208 | $3,165 |
| Diclofenac Sodium ErDiclofenac Sodium | 34 | $2,830 |
| Rosuvastatin Calcium | 111 | $2,411 |
| Metoprolol Succinate | 112 | $2,356 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Miramar
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.